Page 100 - Read Online

Page 18 of 20 Ma et al. J Cancer Metastasis Treat 2022;8:25 https://dx.doi.org/10.20517/2394-4722.2022.17

peripheral T-cell lymphoma. Blood 2016;128:1234-45. DOI PubMed PMC
39. Fujisawa M, Sakata-Yanagimoto M, Nishizawa S, et al. Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell
lymphoma. Leukemia 2018;32:694-702. DOI PubMed PMC
40. Vallois D, Dobay MP, Morin RD, et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other
follicular helper T-cell-derived lymphomas. Blood 2016;128:1490-502. DOI PubMed
41. Rohr J, Guo S, Huo J, et al. Recurrent activating mutations of CD28 in peripheral T-cell lymphomas. Leukemia 2016;30:1062-70.
DOI PubMed PMC
42. Manso R, Rodríguez-Pinilla SM, González-Rincón J, et al. Recurrent presence of the PLCG1 S345F mutation in nodal peripheral T-
cell lymphomas. Haematologica 2015;100:e25-7. DOI PubMed PMC
43. Streubel B, Vinatzer U, Willheim M, Raderer M, Chott A. Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell
lymphoma. Leukemia 2006;20:313-8. DOI
44. Huang Y, Moreau A, Dupuis J, et al. Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper
T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. Am J Surg Pathol 2009;33:682-90.
DOI PubMed PMC
45. Feldman AL, Sun DX, Law ME, et al. Overexpression of syk tyrosine kinase in peripheral T-cell lymphomas. Leukemia
2008;22:1139-43. DOI PubMed PMC
46. Pechloff K, Holch J, Ferch U, et al. The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional
mouse models of peripheral T cell lymphoma. J Exp Med 2010;207:1031-44. DOI PubMed PMC
47. Watatani Y, Sato Y, Miyoshi H, et al. Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by
comprehensive genetic profiling. Leukemia 2019;33:2867-83. DOI
48. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for
advanced non-hodgkin’s lymphoma. N Engl J Med 1993;328:1002-6. DOI PubMed
49. Abramson JS, Feldman T, Kroll-Desrosiers AR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication
in the modern era including impact of frontline therapy. Ann Oncol 2014;25:2211-7. DOI PubMed PMC
50. Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients
with T-cell lymphoma treated in studies of the German high-grade non-hodgkin lymphoma study group. Blood 2010;116:3418-25.
DOI PubMed
51. Cederleuf H, Bjerregård Pedersen M, Jerkeman M, Relander T, d’Amore F, Ellin F. The addition of etoposide to CHOP is associated
with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study. Br J Haematol
2017;178:739-46. DOI PubMed
52. Deng S, Lin S, Shen J, Zeng Y. Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis.
Onco Targets Ther 2019;12:2335-42. DOI PubMed PMC
53. Lai GM, Chen YN, Mickley LA, Fojo AT, Bates SE. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity
in human colon carcinoma cell lines. Int J Cancer 1991;49:696-703. DOI PubMed
54. Horwitz S, O’Connor OA, Pro B, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab
vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol 2022;33:288-98. DOI PubMed
55. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse
large-B-cell lymphoma. N Engl J Med 2002;346:235-42. DOI PubMed
56. Wang ES, O’Connor O, She Y, Zelenetz AD, Sirotnak FM, Moore MA. Activity of a novel anti-folate (PDX, 10-propargyl 10-
deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk
Lymphoma 2003;44:1027-35. DOI PubMed
57. O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results
from the pivotal PROPEL study. J Clin Oncol 2011;29:1182-9. DOI
58. Advani RH, Ansell SM, Lechowicz MJ, et al. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP)
Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T-
cell consortium trial. Br J Haematol 2016;172:535-44. DOI PubMed PMC
59. Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory
peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012;30:631-6. DOI
60. Foss F, Horwitz S, Pro B, et al. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable
disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol 2016;9:22. DOI
61. Foss F, Horwitz S, Pro B, et al. Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma:
prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol 2017;10:154. DOI PubMed
PMC
62. Chiappella A, Carniti C, Re A, et al. Adding romidepsin to CHOEP in first line treatment of peripheral T-Cell lymphomas does not
improve the response rate: final analysis of phase II PTCL13 study. Blood 2021;138:134-134. DOI
63. Ruan J, Moskowitz AJ, Mehta-Shah N, et al. High Rates of remission with the initial treatment of oral azacitidine plus CHOP for
peripheral T-Cell lymphoma (PTCL): clinical outcomes and biomarker analysis of a multi-center phase II study. Blood 2021;138:138.
DOI
64. Wulf GG, Altmann B, Ziepert M, et al. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: